title: Adverse periocular reactions to five types of prostaglandin analogs.
abstract: OBJECTIVE
  We investigated the appearance frequency of eyelid pigmentation and eyelash bristles after the use of five types of prostaglandin (PG) analogs.
  
  
  METHODS
  This study included 250 eyes from 250 patients diagnosed with primary open-angle glaucoma or ocular hypertension who were treated with either latanoprost, travoprost, tafluprost, bimatoprost, or isopropyl unoprostone for >3 months in only one eye. Photographs of both eyes were obtained, and the images were assessed by three ophthalmologists who were masked to treatment type. The existence of eyelid pigmentation and eyelash bristles was judged, and images of the left and right eyes were compared. Subjective symptoms regarding the existence of eyelid pigmentation and eyelash bristles were investigated through a questionnaire.
  
  
  RESULTS
  There was no significant difference between the five types of medications with regard to eyelid pigmentation (P=0.537). Use of isopropyl unoprostone resulted in a significantly lower incidence of eyelash bristles (P<0.0001). The questionnaire investigation showed that eyelid pigmentation and eyelash bristles were significantly more frequent with travoprost (42.0% and 42.0%, respectively) and bimatoprost (58.0% and 60.0%, respectively) than with other three medications (P<0.0001).
  
  
  CONCLUSIONS
  The appearance frequency of eyelid pigmentation was similar among the five types of PG analogs studied, and eyelash bristles appeared less frequently with isopropyl unoprostone use. Patients are conscious of eyelash bristles; therefore, these adverse effects should be sufficiently explained to patients before PG administration.
authors.affiliation: Inouye Eye Hospital, Tokyo, Japan. inoue-k@inouye-eye.or.jp
authors.forename: K
authors.initials: K
authors.lastname: Inoue
authors.forename: M
authors.initials: M
authors.lastname: Shiokawa
authors.forename: R
authors.initials: R
authors.lastname: Higa
authors.forename: M
authors.initials: M
authors.lastname: Sugahara
authors.forename: T
authors.initials: T
authors.lastname: Soga
authors.forename: M
authors.initials: M
authors.lastname: Wakakura
authors.forename: G
authors.initials: G
authors.lastname: Tomita
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000577:Amides / Q000009:adverse effects; D000959:Antihypertensive Agents / Q000009:adverse effects*; D000069580:Bimatoprost; D003008:Cloprostenol / Q000009:adverse effects / Q000031:analogs & derivatives; D015237:Dinoprost / Q000009:adverse effects / Q000031:analogs & derivatives; D005140:Eyelashes / Q000187:drug effects*; D005141:Eyelid Diseases / Q000139:chemically induced*; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy; D011446:Prospective Studies; D011460:Prostaglandins F / Q000009:adverse effects; D011461:Prostaglandins F, Synthetic / Q000009:adverse effects; D011465:Prostaglandins, Synthetic / Q000009:adverse effects*; D012880:Skin Pigmentation / Q000187:drug effects*; D011795:Surveys and Questionnaires; D000069557:Travoprost
chemical_list: D000577:Amides; D000959:Antihypertensive Agents; D011460:Prostaglandins F; D011461:Prostaglandins F, Synthetic; D011465:Prostaglandins, Synthetic; C485333:tafluprost; D003008:Cloprostenol; C072630:isopropyl unoprostone; D000077338:Latanoprost; D015237:Dinoprost; D000069580:Bimatoprost; D000069557:Travoprost